The Spectrum of Inflammatory Acquired Demyelinating Syndromes in Children

Banwell, 2009, Incidence of acquired demyelination of the CNS in Canadian children, Neurology, 72, 232, 10.1212/01.wnl.0000339482.84392.bd Ketelslegers, 2012, Incidence of acquired demyelinating syndromes of the CNS in Dutch children: A nationwide study, J Neurol, 259, 1929, 10.1007/s00415-012-6441-6 Langer-Gould, 2011, Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children, Neurology, 77, 1143, 10.1212/WNL.0b013e31822facdd Krupp, 2013, International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: Revisions to the 2007 definitions, Mult Scler, 19, 1261, 10.1177/1352458513484547 Ketelslegers, 2015, Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort, Mult Scler, 21, 1513, 10.1177/1352458514566666 Hintzen, 2016, Pediatric acquired CNS demyelinating syndromes: Features associated with multiple sclerosis, Neurology, 87, S67, 10.1212/WNL.0000000000002881 Waldman, 2014, Multiple sclerosis in children: An update on clinical diagnosis, therapeutic strategies, and research, Lancet Neurol, 13, 936, 10.1016/S1474-4422(14)70093-6 Banwell, 2011, Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: A prospective national cohort study, Lancet Neurol, 10, 36 Absoud, 2013, Paediatric acquired demyelinating syndromes: Incidence, clinical and magnetic resonance imaging features, Mult Scler, 19, 76, 10.1177/1352458512445944 Ketelslegers, 2011, Disease course and outcome of acute disseminated encephalomyelitis is more severe in adults than in children, Mult Scler, 17, 441, 10.1177/1352458510390068 Wong, 2017, Evolution of MRI abnormalities in paediatric acute disseminated encephalomyelitis, Eur J Paediatr Neurol, 21, 300, 10.1016/j.ejpn.2016.08.014 Huppke, 2013, Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients, Mult Scler, 19, 941, 10.1177/1352458512466317 Banwell, 2008, Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders, Neurology, 70, 344, 10.1212/01.wnl.0000284600.80782.d5 Wingerchuk, 2015, International consensus diagnostic criteria for neuromyelitis optica spectrum disorders, Neurology, 85, 177, 10.1212/WNL.0000000000001729 Chitnis, 2016, Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report, Neurology, 86, 245, 10.1212/WNL.0000000000002283 Van Pelt, 2014, Application of the 2012 revised diagnostic definitions for paediatric multiple sclerosis and immune-mediated central nervous system demyelination disorders, J Neurol Neurosurg Psychiatry, 85, 790, 10.1136/jnnp-2013-306850 Sadaka, 2012, 2010 McDonald criteria for diagnosing pediatric multiple sclerosis, Ann Neurol, 72, 211, 10.1002/ana.23575 Schwarz, 2016, B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis, Neurol Neuroimmunol Neuroinflamm, 4, e309, 10.1212/NXI.0000000000000309 Quintana, 2014, Epitope spreading as an early pathogenic event in pediatric multiple sclerosis, Neurology, 83, 2219, 10.1212/WNL.0000000000001066 Hemmer, 2002, New concepts in the immunopathogenesis of multiple sclerosis, Nat Rev Neurosci, 3, 291, 10.1038/nrn784 Cala, 2016, T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis, J Neuroimmunol, 297, 1, 10.1016/j.jneuroim.2016.04.015 Ishizu, 2006, CSF cytokine and chemokine profiles in acute disseminated encephalomyelitis, J Neuroimmunol, 175, 52, 10.1016/j.jneuroim.2006.03.020 Kothur, 2016, Utility of CSF cytokine/chemokines as markers of active intrathecal inflammation: Comparison of demyelinating, anti-NMDAR and enteroviral encephalitis, PLoS One, 11, e0161656, 10.1371/journal.pone.0161656 Kothur, 2016, B-cell, Th17, and neutrophil related cerebrospinal fluid cytokine/chemokines are elevated in MOG antibody associated demyelination, PLoS One, 11, e0149411, 10.1371/journal.pone.0149411 Pröbstel, 2011, Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis, Neurology, 77, 580, 10.1212/WNL.0b013e318228c0b1 Compston, 2008, Multiple sclerosis, Lancet, 372, 1502, 10.1016/S0140-6736(08)61620-7 Sadovnick, 2012, Genetic background of multiple sclerosis, Autoimmun Rev, 11, 163, 10.1016/j.autrev.2011.05.007 Gale, 1995, Migrant studies in multiple sclerosis, Prog Neurobiol, 47, 425, 10.1016/0301-0082(95)80008-V Jelinek, 2015, Latitude, sun exposure and vitamin D supplementation: Associations with quality of life and disease outcomes in a large international cohort of people with multiple sclerosis, BMC Neurol, 15, 132, 10.1186/s12883-015-0394-1 Farez, 2015, Melatonin contributes to the seasonality of multiple sclerosis relapses, Cell, 162, 1338, 10.1016/j.cell.2015.08.025 Makhani, 2015, Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination, Mult Scler, 22, 385, 10.1177/1352458515595876 Pittas, 2009, Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis, J Neurol, 256, 577, 10.1007/s00415-009-0120-2 Lunny, 2014, Physical trauma and risk of multiple sclerosis: A systematic review and meta-analysis of observational studies, J Neurol Sci, 336, 13, 10.1016/j.jns.2013.08.011 Munger, 2013, Childhood body mass index and multiple sclerosis risk: A long-term cohort study, Mult Scler, 19, 1323, 10.1177/1352458513483889 Langer-Gould, 2013, Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome, Neurology, 80, 548, 10.1212/WNL.0b013e31828154f3 Hucke, 2016, Implications of dietary salt intake for multiple sclerosis pathogenesis, Mult Scler, 22, 133, 10.1177/1352458515609431 Renoux, 2007, Natural history of multiple sclerosis with childhood onset, N Engl J Med, 356, 2603, 10.1056/NEJMoa067597 MacAllister, 2005, Cognitive functioning in children and adolescents with multiple sclerosis, Neurology, 64, 1422, 10.1212/01.WNL.0000158474.24191.BC Amato, 2014, Neuropsychological features in childhood and juvenile multiple sclerosis: Five-year follow-up, Neurology, 83, 1432, 10.1212/WNL.0000000000000885 Julian, 2013, Cognitive impairment occurs in children and adolescents with multiple sclerosis:Results from a United States network, J Child Neurol, 28, 102, 10.1177/0883073812464816 Amato, 2008, Cognitive and psychosocial features of childhood and juvenile MS, Neurology, 70, 1891, 10.1212/01.wnl.0000312276.23177.fa Amato, 2010, Cognitive and psychosocial features in childhood and juvenile MS: Two-year follow-up, Neurology, 75, 1134, 10.1212/WNL.0b013e3181f4d821 Baruch, 2016, Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis, Mult Scler, 22, 354, 10.1177/1352458515588781 MacAllister, 2009, Fatigue and quality of life in pediatric multiple sclerosis, Mult Scler, 15, 1502, 10.1177/1352458509345902 Goretti, 2012, Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis, Mult Scler, 18, 329, 10.1177/1352458511420846 Ketelslegers, 2010, Fatigue and depression in children with multiple sclerosis and monophasic variants, Eur J Paediatr Neurol, 14, 320, 10.1016/j.ejpn.2009.09.004 Mowry, 2010, Health-related quality of life is reduced in pediatric multiple sclerosis, Pediatric Neurology, 43, 97, 10.1016/j.pediatrneurol.2010.03.007 Tenembaum, 2002, Acute disseminated encephalomyelitis: A long-term follow-up study of 84 pediatric patients, Neurology, 59, 1224, 10.1212/WNL.59.8.1224 Suppiej, 2014, Long-term neurocognitive outcome and quality of life in pediatric acute disseminated encephalomyelitis, Pediatr Neurol, 50, 363, 10.1016/j.pediatrneurol.2013.12.006 Beatty, 2016, Long-term neurocognitive, psychosocial, and magnetic resonance imaging outcomes in pediatric-onset acute disseminated encephalomyelitis, Pediatr Neurol, 57, 64, 10.1016/j.pediatrneurol.2016.01.003 Jacobs, 2004, Neuropsychological outcome after acute disseminated encephalomyelitis: Impact of age at illness onset, Pediatr Neurol, 31, 191, 10.1016/j.pediatrneurol.2004.03.008 Waldman, 2011, Management of pediatric central nervous system demyelinating disorder: Consensus of United States neurologists, J Child Neurol, 26, 675, 10.1177/0883073810395141 Nosadini, 2016, Intravenous immunoglobulin in paediatric neurology: Safety, adherence to guidelines, and long-term outcome, Dev Med Child Neurol, 58, 1180, 10.1111/dmcn.13159 Bigi, 2015, Outcomes after early administration of plasma exchange in pediatric central nervous system inflammatory demyelination, J Child Neurol, 30, 874, 10.1177/0883073814545883 Yeh, 2011, Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis, Arch Neurol, 68, 437, 10.1001/archneurol.2010.325 Chitnis, 2012, Consensus statement: Evaluation of new and existing therapeutics for pediatric multiple sclerosis, Mult Scler, 18, 116, 10.1177/1352458511430704 Naismith, 2016, Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-NO, Mult Scler, 22, 1400, 10.1177/1352458516644676 Giovannoni, 2016, Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-YES, Mult Scler, 22, 1397, 10.1177/1352458516650737 1995, The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, Neurology, 45, 1277 1998, PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group, Lancet, 352, 1498 Jacobs, 1996, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, Ann Neurol, 39, 285, 10.1002/ana.410390304 Calabresi, 2014, Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): A randomised, phase 3, double-blind study, Lancet Neurol, 13, 657, 10.1016/S1474-4422(14)70068-7 Ghezzi, 2009, Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: The Italian experience, Neurol Sci, 30, 193, 10.1007/s10072-009-0083-1 Tenembaum, 2013, Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: A retrospective study, J Child Neurol, 28, 849, 10.1177/0883073813488828 Comi, 2001, Ann Neurol, 49, 290, 10.1002/ana.64 Ford, 2010, Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the US prospective open-label study of glatiramer acetate, Mult Scler, 16, 342, 10.1177/1352458509358088 Comi, 2009, Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial, Lancet, 374, 1503, 10.1016/S0140-6736(09)61259-9 Khan, 2013, Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis, Ann Neurol, 73, 705, 10.1002/ana.23938 Kornek, 2003, Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis, Neuropediatrics, 34, 120, 10.1055/s-2003-41274 Makhani, 2013, Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS, Neurology, 81, 850, 10.1212/WNL.0b013e3182a2cc4a Kappos, 2010, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, 362, 387, 10.1056/NEJMoa0909494 Cohen, 2010, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N Engl J Med, 362, 402, 10.1056/NEJMoa0907839 Calabresi, 2014, Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Neurol, 13, 545, 10.1016/S1474-4422(14)70049-3 Tully, 2015, Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod, Neurology, 84, 1999, 10.1212/WNL.0000000000001556 D'Amico, 2016, Treatment-related progressive multifocal leukoencephalopathy in multiple sclerosis: A comprehensive review of current evidence and future needs, Drug Saf, 39, 1163, 10.1007/s40264-016-0461-6 Fragoso, 2015, Fingolimod prescribed for the treatment of multiple sclerosis in patients younger than age 18 years, Pediatr Neurol, 53, 166, 10.1016/j.pediatrneurol.2015.03.024 Gold, 2012, Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis, N Engl J Med, 367, 1098, 10.1056/NEJMoa1114287 Makhani, 2016, Oral dimethyl fumarate in children with multiple sclerosis: A dual-center study, Pediatr Neurol, 57, 101, 10.1016/j.pediatrneurol.2016.01.010 O'Connor, 2011, Randomized trial of oral teriflunomide for relapsing multiple sclerosis, N Engl J Med, 365, 1293, 10.1056/NEJMoa1014656 Vermersch, 2014, Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: A randomised, controlled phase 3 trial, Mult Scler, 20, 705, 10.1177/1352458513507821 Polman, 2006, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, 354, 899, 10.1056/NEJMoa044397 Rudick, 2006, Natalizumab plus interferon beta-1a for relapsing multiple sclerosis, N Engl J Med, 354, 911, 10.1056/NEJMoa044396 Bloomgren, 2012, Risk of natalizumab-associated progressive multifocal leukoencephalopathy, N Engl J Med, 366, 1870, 10.1056/NEJMoa1107829 Ghezzi, 2015, Natalizumab in the pediatric MS population: Results of the Italian registry, BMC Neurol, 15, 174, 10.1186/s12883-015-0433-y Hauser, 2008, B-cell depletion with rituximab in relapsing-remitting multiple sclerosis, N Engl J Med, 358, 676, 10.1056/NEJMoa0706383 Beres, 2014, Rituximab use in pediatric central demyelinating disease, Pediatr Neurol, 51, 114, 10.1016/j.pediatrneurol.2014.02.007 Salzer, 2016, Rituximab in paediatric onset multiple sclerosis: A case series, J Neurol, 263, 322, 10.1007/s00415-015-7979-x Dale, 2014, Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease, Neurology, 83, 142, 10.1212/WNL.0000000000000570 Smith, 2005, A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta, Mult Scler, 11, 573, 10.1191/1352458505ms1210oa Makhani, 2009, Cyclophosphamide therapy in pediatric multiple sclerosis, Neurology, 72, 2076, 10.1212/WNL.0b013e3181a8164c Cohen, 2012, Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial, Lancet, 380, 1819, 10.1016/S0140-6736(12)61769-3 Hauser, 2017, Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis, N Engl J Med, 376, 221, 10.1056/NEJMoa1601277 Kappos, 2015, Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis, N Engl J Med, 373, 1418, 10.1056/NEJMoa1501481 Gorman, 2012, Daclizumab use in patients with pediatric multiple sclerosis, Arch Neurol, 69, 78, 10.1001/archneurol.2011.581 Atkins, 2016, Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: A multicentre single-group phase 2 trial, Lancet, 388, 576, 10.1016/S0140-6736(16)30169-6 Wootla, 2016, Recent advances in monoclonal antibody therapies for multiple sclerosis, Expert Opin Biol Ther, 16, 827, 10.1517/14712598.2016.1158809 Shen, 2008, Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency, Nat Neurosci, 11, 1024, 10.1038/nn.2172 Warrington, 2000, Human monoclonal antibodies promote remyelination of spinal cord lesions in a model of multiple sclerosis, PNAS, 97, 6820, 10.1073/pnas.97.12.6820 Warrington, 2004, Neuron-binding human monoclonal antibodies support central nervous system neurite extension, J Neuropath Exp Neurol, 63, 461, 10.1093/jnen/63.5.461 Costanzi, 2011, Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica, Neurology, 77, 659, 10.1212/WNL.0b013e31822a2780 Elsone, 2014, Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: A multicentre retrospective observational study from the UK, Mult Scler, 20, 1533, 10.1177/1352458514525870 Huh, 2014, Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder, JAMA Neurol, 71, 1372, 10.1001/jamaneurol.2014.2057 Jacob, 2009, Treatment of neuromyelitis optica with mycophenolate mofetil: Retrospective analysis of 24 patients, Arch Neurol, 66, 1128, 10.1001/archneurol.2009.175 Mahmood, 2011, Efficacy and safety of rituximab in pediatric neuromyelitis optica, J Child Neurol, 26, 244, 10.1177/0883073810381445 Nosadini, 2016, Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder, Neurol Neuroimmunol Neuroinflamm, e188, 10.1212/NXI.0000000000000188 Baumann, 2016, Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases, Mult Scler, 22, 1821, 10.1177/1352458516631038 Shimizu, 2010, IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum, Neurology, 75, 1423, 10.1212/WNL.0b013e3181f8832e